Acrux signs second distribution agreement with CSL
Tuesday, 30 November, 2004
Acrux (ASX: ACR) has signed a second distribution agreement with CSL (ASX: CSL), giving CSL the rights to distribute Acrux's Fentanyl MDTS treatment for severe pain.
The product, which is undergoing Phase I clinical development, will be distributed by CSL Pharmaceuticals in Australia and New Zealand. Acrux will receive both an upfront payment plus royalties on net sales.
Earlier this year, CSL agreed to distribute Acrux's testosterone MDTS treatment for low testosterone levels and sexual dysfunction in women.
Hormone therapy shifts body proteins to match gender identity
Researchers have discovered that gender-affirming hormone therapy can alter body proteins to...
Targeting 'molecular bodyguards' weakens prostate cancer cells
Research reveals that two enzymes — PDIA1 and PDIA5 — act as 'molecular...
Females found to carry a higher genetic risk of depression
An international team of scientists has discovered about twice as many genetic 'flags'...
